𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C

✍ Scribed by Stefan Zeuzem; Uwe Hopf; Vicente Carreno; Moisés Diago; Mitchell Shiffman; Stefan Grüne; Francis J. Dudley; Ashok Rakhit; Karen Rittweger; Sing Hiem Yap; Raymond S. Koff; Howard C. Thomas

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
114 KB
Volume
29
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiviral effect of human recombinant in
Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus
✍ Lee, Jung-Hun; Teuber, Gerlinde; von Wagner, Michael; Roth, Willi Kurt; Zeuzem, 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 2 views

The heterogeneity of hepatitis C virus (HCV) is due to the continuous and high replication rate, the low fidelity of the RNA-dependent RNA polymerase, and the immune surveillance of the host. Interleukin-12 (IL-12) plays a central role in mounting an effective cellular immune response directed towar

A pilot study of recombinant interleukin
A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C
✍ M Pardo; I Castillo; H Oliva; A Fernandez-Flores; R Barcena; M A de Peuter; V Ca 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 1 views

The optimal and safer interleukin-2 (IL-2) dose for treatment of chronic hepatitis C virus (HCV) infection has been studied in 33 HCV-RNA positive patients with chronic hepatitis C. Patients were randomly allocated to receive 5 days per week during 12 weeks IL-2 doses of: 0.9 MIU (n = 10), 1.8 MIU (

Phase I trial of subcutaneous recombinan
Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma
✍ Omar Eton; Michael G. Rosenblum; Sewa S. Legha; Wehei Zhang; Mary Jo East; Agop 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 3 views

## Abstract ## BACKGROUND Interleukin‐2 (IL‐2) has activity in metastatic melanoma when given in high doses by the intravenous (IV) route, but its side effects and effectiveness when given in intermediate to high doses by the subcutaneous (SC) route have not been studied adequately. This study sou

A phase II dose-escalating trial of clev
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
✍ Patrick Marcellin; Herve Mommeja-Marin; Stephen L. Sacks; George K. K. Lau; Dani 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure. Clevudine is a new pyrimidine analog with potent anti-hepatitis B virus (HBV) activity in vitro. A multicenter dose-escalation study evaluated clevudine at 10, 50, 100, and 200 mg o

Production of interleukin-18 and interle
Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy
✍ E. Schvoerer; M.C. Navas; C. Thumann; A. Fuchs; N. Meyer; F. Habersetzer; F. Sto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

## Abstract Interleukin‐12 and ‐18 (IL‐12 and IL‐18) are known to enhance the cytotoxic T‐lymphocyte response synergistically, but their precise involvement in hepatitis C virus (HCV) infection is not well known, especially for IL‐18. Enzyme‐linked immunosorbent assay (ELISA) was used to study the